Neurobo Cash And Short Term Investments from 2010 to 2024
| NRBO Stock | USD 2.40 0.05 2.04% |
Cash And Short Term Investments | First Reported 2015-12-31 | Previous Quarter 27.9 M | Current Value 21.7 M | Quarterly Volatility 9.9 M |
Check Neurobo Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurobo Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.7 K, Interest Expense of 0.0 or Selling General Administrative of 6.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.18. Neurobo financial statements analysis is a perfect complement when working with Neurobo Pharmaceuticals Valuation or Volatility modules.
Neurobo | Cash And Short Term Investments |
Latest Neurobo Pharmaceuticals' Cash And Short Term Investments Growth Pattern
Below is the plot of the Cash And Short Term Investments of Neurobo Pharmaceuticals over the last few years. Short Term Investments is an account in the current assets section of Neurobo Pharmaceuticals balance sheet. This account contains Neurobo Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Neurobo Pharmaceuticals fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Neurobo Pharmaceuticals' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurobo Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Cash And Short Term Investments | 10 Years Trend |
|
Cash And Short Term Investments |
| Timeline |
Neurobo Cash And Short Term Investments Regression Statistics
| Arithmetic Mean | 12,041,453 | |
| Geometric Mean | 4,281,966 | |
| Coefficient Of Variation | 89.14 | |
| Mean Deviation | 9,199,490 | |
| Median | 13,908,000 | |
| Standard Deviation | 10,733,448 | |
| Sample Variance | 115.2T | |
| Range | 33M | |
| R-Value | 0.79 | |
| Mean Square Error | 47.1T | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 1,890,120 | |
| Total Sum of Squares | 1612.9T |
Neurobo Cash And Short Term Investments History
About Neurobo Pharmaceuticals Financial Statements
Neurobo Pharmaceuticals investors utilize fundamental indicators, such as Cash And Short Term Investments, to predict how Neurobo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Cash And Short Term Investments | 22.4 M | 17.8 M |
Pair Trading with Neurobo Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurobo Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurobo Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurobo Stock
| 0.67 | ME | 23Andme Holding | PairCorr |
| 0.84 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.72 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Neurobo Stock
| 0.76 | KZR | Kezar Life Sciences | PairCorr |
| 0.6 | MLYS | Mineralys Therapeutics, Downward Rally | PairCorr |
| 0.34 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Neurobo Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurobo Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurobo Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurobo Pharmaceuticals to buy it.
The correlation of Neurobo Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurobo Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurobo Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurobo Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Neurobo Pharmaceuticals Correlation against competitors. To learn how to invest in Neurobo Stock, please use our How to Invest in Neurobo Pharmaceuticals guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobo Pharmaceuticals. If investors know Neurobo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobo Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.29) | Return On Assets (0.74) | Return On Equity (1.61) |
The market value of Neurobo Pharmaceuticals is measured differently than its book value, which is the value of Neurobo that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Neurobo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Neurobo Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobo Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.